API Makers Must Control Dangerous Impurities Better, FDA Compliance Official Says

The compliance chief for FDA’s center for drugs said API makers need to do a better job of testing their products for impurities to avoid exposing patients to safety risks, as has occurred with at least one supplier’s valsartan API.

More from Manufacturing

More from Compliance